Insights & Innovators: Is Lab Data the Secret Weapon for More Efficient Clinical Trials?
According to the National Institutes of Health (NIH), approximately 80% of research studies fail to meet their enrollment goals within the stated timeframes. Recruitment and trial design challenges can prolong the timeline for phase III studies, driving up costs and delaying market entry. While many sponsors use aggregated data and predictive analytics to improve the […]
Insights & Innovators: Generating Rapid Response to Health Authority Inquiry Using Real-World Data and Advanced Analytics
Dr. Xia recently spoke about the ways in which real-world data and advanced analytics using Panalgo’s IHD Analytics platform can be leveraged to quickly and efficiently to respond to an inquiry from a health authority. Q: Dr. Xia, can you provide some background on what prompted the need for a rapid study? A: Takeda received […]
Insights & Innovators: A Q&A with Greg Norman and Poorva Nemlekar from Dexcom
In part one of this two-part blog series, Greg Norman and Katia Hannah introduced us to their team’s research and discussed one study they conducted in IHD. In this second and final part of the series, we’ll hear more about the team’s exploratory work and insights from the study titled Association Between Change in HbA1c […]
Insights & Innovators: A Q&A with Greg Norman and Katia Hannah from Dexcom
In this two-part blog series, we’ll hear from Greg, Katia, and Poorva on insights and learnings from their use of the IHD Analytics platform and get an in-depth look at two retrospective real-world studies that they conducted. In this first part, Greg and Katia introduce us to their team’s work and discuss one study titled […]
The Importance of Accounting for Time-Related Bias in Single-Arm Trials with Historical Controls (Part 2)
In our previous blog post, we sat down with Dr. Samy Suissa, the co-founder and principal investigator of the Canadian Network for Observational Drug Effect Studies, to discuss the main themes from his recent journal article in Epidemiology. Namely, he argues that while single-arm trials with historical controls are gaining recognition in clinical trial design, pharma companies […]
The Importance of Accounting for Time-Related Bias in Single-Arm Trials with Historical Controls (Part 1)
Randomized control trials (RCTs) are typically heralded as the gold standard in clinical trial design. However, regulatory agencies are increasingly recognizing the role of single-arm trials that leverage historical controls, especially within the rare disease space. Yet while these single-arm trials could have important ramifications for getting much-needed drugs to market quicker, pharma companies need […]
Leveraging RWD in Observational Studies: Understanding the Implications of Time-Related Biases
Dr. Suissa spoke at Panalgo’s 2021 IHD User conference about the implications of relying on observational studies that may have time-related biases and how to solve for them. Here are the key highlights from his talk. Q: Dr. Suissa, why is it important to consider time-related biases in observational studies? A: Observational studies have become […]
Innovating RWE Organizations: Learning from the Past and Looking to the Future
Chris spoke at Panalgo’s 2021 IHD User conference about the evolution of Real-World Evidence (RWE) and how pharma needs to reimagine its function – to better enable clinical discovery, development and the commercialization of drug therapies in a post-COVID-19 world. Here are the key highlights from his talk. Q: How has COVID-19 changed our thinking […]
Viewpoint: Life Sciences Should View Commercial Analytics Teams as a Revenue Generator
Vijay talks about the importance of speed and data analytics in a world of exponential data growth and how life sciences organizations should look at the commercial team as a revenue generator, not a cost center. It’s important to note the views and opinions expressed here are Vijay’s own and do not reflect those of […]
Interview with Dr. Mark Friedman on Covid-19 Complications and the Use of Real-World Data
Q: What do we know about the long-term consequences of Covid-19? A: As of early December, Covid-19 infections have topped 64.66 million worldwide and an estimated 13.93 million in the US. We know that many infected people have minimal or no symptoms, some have a flu-like illness, and others may progress to a more severe illness […]